Global footprint Nova Eye Medical's glaucoma devices are used by eye surgeons in more than 100 countries, signaling broad cross-sell potential for the iTrack MIGS portfolio and Molteno3 through existing distributor networks and regional approvals.

Congress opportunities Active participation in leading ophthalmology congresses such as DOG Annual Congress and ESCRS in 2025 creates high-value touchpoints for live demonstrations, surgeon education, and lead generation around iTrack canaloplasty solutions.

Funding momentum Recent financing rounds and expansion objectives indicate available capital to accelerate regional sales force growth, partnerships, and scaling of manufacturing and distribution capabilities.

US momentum Record US sales for iTrack Advance and a clear focus on the US market point to expansion opportunities with hospital networks, KOL engagement, and institutional purchasing arrangements.

Strategic partnerships In a competitive glaucoma device landscape, Nova Eye's focused MIGS and canaloplasty offerings create potential for exclusive or prioritized distribution partnerships, coupled training, and co-marketing to differentiate from larger incumbents.